HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained an $87 price target on the stock.

May 09, 2024 | 6:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating and an $87 price target for Legend Biotech.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in LEGN's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100